5 December 2025
Latham & Watkins Advises Gate Bioscience in US$65 Million Series B
Advising firms
Deal team
4 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Kathleen Wells Lead | Latham & Watkins LLP | Partner | Emerging Companies & Growth | Bay Area |
| Christopher Pham | Latham & Watkins LLP | Associate | Emerging Companies & Growth | Not stated |
| Jack McKay | Latham & Watkins LLP | Associate | Emerging Companies & Growth | Not stated |
| Wes Dantzler | Latham & Watkins LLP | Not stated | Emerging Companies & Growth | Not stated |
Stated terms
- Stated value
- USD 65m (US$65 million)
- What the figure measures
- Total transaction value
- Client
- Gate BioscienceIssuer
- Counterparties
- Forbion (Investor)
Eli Lilly and Company (Investor)
Versant Ventures (Investor)
Andreessen Horowitz (a16z) Bio + Health (Investor)
GV (Investor)
ARCH Venture Partners (Investor)